Skip to Content

Advanced Medical Solutions: Unfavorable Reimbursement Shift Drives Fair Value Estimate 18% Lower

""

We lower our fair value estimate on narrow-moat Advanced Medical Solutions AMS to GBX 278 per share, from GBX 340, after reducing our 2023-25 projections to reflect the ripple effects of unfavorable reimbursement decisions by several local Medicare contractors in the U.S. This shift primarily affects the cellular and/or tissue-based products, or CTPs, in advanced wound care—a small, but fast-growing niche mainly centered in the U.S. Not only have these Medicare contractors reduced the number of these biological tissue healing products covered per wound episode, they’ve also limited coverage of only certain wounds and only certain brands. Unfortunately for AMS, its client Organogenesis has lost reimbursement for PuraPly, which accounted for roughly 40% of consolidated revenue at Organogenesis in 2022. Accordingly, we reduce our estimates for the original equipment manufacturer segment through 2025 to reflect the duration of AMS’ contract with Organogenesis. While this coverage change weighs on our valuation, it doesn’t have much impact on AMS’ narrow economic moat, which stems from its intangible assets. We see little to change our perspective on AMS’ ability to innovate.

In previous situations involving Medicare cuts, we’ve sometimes seen the Centers for Medicare & Medicaid Services walk back the reimbursement reductions, especially when such cuts have materially compromised patient access. In this case, we’re skeptical that the Medicare contractors will be compelled to return to the prior reimbursement levels for several reasons. First, there are plenty of substitutes in this highly fragmented niche of CTPs, which suggests access is not an issue. Second, CTP studies have demonstrated that the use of 4-8 products per wound episode is often all that’s needed to heal the average wound (though size and patient comorbidity are key elements that can drive the number higher), and the four per episode that will now be reimbursed just hits the bottom of the range.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

More in Stocks

About the Author

Debbie Wang

Senior Equity Analyst
More from Author

Debbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device, diagnostics, and animal health industries. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.

Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald's, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.

Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.

Sponsor Center